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Abstract
Background: 2',3'-Cyclic nucleotide 3'-phosphodiesterase (CNP), one of the promising candidate
genes for schizophrenia, plays a key part in the oligodendrocyte function and in myelination. The
present study aims to investigate the relationship between CNP and schizophrenia in the Chinese
population and the effect of different factors on the expression level of CNP in schizophrenia.
Methods: Five CNP single nucleotide polymorphisms (SNPs) were investigated in a Chinese Han
schizophrenia case-control sample set (n = 180) using direct sequencing. The results were included
in the following meta-analysis. Quantitative real-time polymerase chain reaction (PCR) was
conducted to examine CNP expression levels in peripheral blood lymphocytes.
Results: Factors including gender, genotype, sub-diagnosis and antipsychotics-treatment were
found not to contribute to the expression regulation of the CNP gene in schizophrenia. Our meta-
analysis produced similar negative results.
Conclusion: The results suggest that the CNP gene may not be involved in the etiology and
pathology of schizophrenia in the Chinese population.
Background
There is accumulating evidence pointing to abnormalities
in oligodendrocyte function and myelination as critical fac-
tors in the etiology and pathology of schizophrenia[1,2].
Myelination and factors that affect myelination, such as the
oligodendroglia function, are critical processes that could
profoundly affect neuronal connectivity, especially given
the diffuse distribution of oligodendrocytes and the wide-
spread distribution of brain regions that have been impli-
cated in schizophrenia. A series of micro-array studies have
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indicated significantly reduced expression levels of oli-
godendrocyte and myelin-related genes in the brains of
schizophrenics compared with unaffected controls [3-7].
2',3'-Cyclic nucleotide 3'-phosphodiesterase (CNP) is used
as a marker protein of myelin-forming glial cells. In brain
development, CNP is distributed in cells of the oligodendro-
cyte lineage and is maintained throughout life [8]. Lower
expression levels of CNP have been detected in the postmor-
tem brains of schizophrenic patients[3,7,9]. Hakak et al.
used an expression microarray in the postmortem dorsola-
teral prefrontal cortex of schizophrenics and controls and
detected notable differential expression of myelination-
related genes, suggesting a disruption oligodendrocyte func-
tion in schizophrenics[3]. Tkachev et al. found that the
brains of schizophrenia and bipolar patients showed down-
regulation of key oligodendrocyte and myelination genes, as
well as of transcription factors that regulate these genes, com-
pared with control brains[9]. In post-mortem studies of the
anterior frontal cortex Flynn et al. found lower immunoreac-
tivity of protein encoded by the CNP gene in schizophrenia
patients (P = 0.05)[10]. In a case-control study Peirce et al.
identified significant association between the exonic SNP
rs2070106 and CNP  expression (P  < 0.001) and lower
expression levels of the A allele (P = 0.04) in white subjects
from the United Kingdom and Ireland [11]. CNP maps to
17q21.2, a region which shows strong evidence for linkage
with schizophrenia as indicated by a study in a single pedi-
gree (logarithm odds score = 8.32, genomewide P < 0.02)
[12]. Byne et al. found CNP to be more highly expressed in
females than males across all nuclei, suggesting that other
factors such as gender may be involved in oligodendrocyte
functions linked to schizophrenia[13].
A number of studies have recently been carried out on
transgenic mice to clarify the role of CNP. Lappe-Siefke et
al. showed that CNP-deficient mice displayed a reduction
in overall brain size, enlarged ventricles and corpus callo-
sum atrophy, features which were also observed in schiz-
ophrenia patients[8]. Rasband et al. reported that CNP-
null mice exhibited disrupted axon-glia interactions in the
central nervous system, factors which may also be impli-
cated in schizophrenia[14].
To further investigate the role of the CNP gene locus in
schizophrenia susceptibility, we genotyped five SNPs
(rs4796750, rs8078650, rs2070106, rs11079028 and
rs4796751) and performed quantitative real-time PCR to
determine the factors associated with gene expression and
a meta-analysis to investigate association between the
CNP gene and schizophrenia.
Methods
Subjects
A total of 86 unrelated schizophrenia patients (29 males
and 57 females with a mean age of 53.8 years, SD = 11.5),
and 94 control individuals (41 males and 53 females with
a mean age of 51.9 years, SD = 11.3) were tested for the
expression study. The average onset age of disease was
26.6, SD = 10.4. Cases and controls underwent a clinical
interview administered by two independent senior psy-
chiatrists, based on Diagnostic and Statistical Manual of
Mental Disorders, version IV (DSM-IV) (American Psychi-
atric Association). Those identified as schizophrenia
patients were then diagnosed for inclusion in subgroups
as follows: undifferentiated (n = 62), paranoid (n = 18),
disorganized (n = 3), catatonia (n = 2), residual (n = 1).
No structural diagnostic interview method was used. All
the cases were hospitalized and recruited from the
Changning Institute of Mental Health (the Bio-X Center
Hospital) in Shanghai, East China. The controls were
drawn from the general population in Shanghai. None
had a history of psychotic disorders. All subjects were Chi-
nese Han in origin. A written informed consent for the
study, reviewed and approved by the Shanghai Ethics
Committee of Human Genetic Resources, was obtained
from all participants.
All patients were subjected to a washout period of more
than eight weeks and then treated with a single antipsy-
chotic chosen according to individual clinical assessment
as follows: 43 patients with chlorpromazine at a daily
dose ranging from 100 to 500 mg/d, 4 patients with risp-
eridone from 0.5 to 3 mg/d, 11 patients with aripiprazole
from 10 to 20 mg/d, and 23 patients with clozapine from
25 to 250 mg/d. The dosage was varied in individual cases
where there was intolerance to the maximum dosage.
Genotyping
Genomic DNA was extracted from venous blood using a
modified phenol/chloroform method. For SNP selection,
we used the HapMap database http://www.hapmap.org
and included five SNPs (rs4796750, rs8078650,
rs2070106, rs11079028 and rs4796751) from the Chi-
nese section. PCR amplifications of these five SNPs in the
CNP  gene were first performed for all subjects on the
GeneAmp PCR 9700 System and then genotyped using
direct sequencing on an ABI 3100 genetic analyzer using
the BigDye Terminator Cycle Sequencing Kit (Applied
Biosystems).
RNA Extraction and cDNA Synthesis
Total RNA was extracted using Trizol reagent. RNA integ-
rity was confirmed by direct visualization of 18S and 28S
rRNA bands after agarose-gel electrophoresis. RNA sam-
ples were reverse transcribed using the SuperScript first-
strand synthesis system (Invitrogen) and random hexam-
ers.
Real-Time Quantitative PCR Expression Assay
We performed real-time PCR on the ABI 7900 system
(Applied Biosystems). Reactions were performed in a 10-BMC Medical Genetics 2009, 10:31 http://www.biomedcentral.com/1471-2350/10/31
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ul volume including diluted cDNA samples, primers, and
SYBR Green I Mastermix (Applied Biosystems). We col-
lected real-time PCR data using SDS software (version 2.1
[Applied Biosystems]). Both beta-actin (ACTB) and CNP
were tested four times for each sample.
Statistical Analysis
Case-control study
Allele and genotype frequencies were calculated using the
online software SHEsis http://analysis.bio-x.cn[15]. The
pairwise linkage disequilibrium (LD) and haplotype anal-
ysis were conducted on Haploview software version 3.11
(available at http://www.broad.mit.edu/mpg/haploview/
index.php). Group comparisons for the effect of gender,
genotype, subtype, and specific drug on the expression
level of CNP were analyzed using a t test and one-way
ANOVA test on SPSS for Windows, version 15.0.
Meta-analysis
Eligible studies had to meet all of the following criteria: (1)
they were published in peer-reviewed journals, (2) they
were independent studies using original data, (3) they pro-
vided sufficient data to calculate the odds ratio (OR) with
confidence interval (CI) and P-value, (4) they were case-
control association studies investigating CNP  polymor-
phisms, (5) they described the relevant genotyping primers,
machines and protocols or provided reference to them, (6)
they diagnosed schizophrenic patients according to DSM-
IV criteria, and (7) they used healthy individuals as con-
trols. We searched PubMed citations http://
www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed up to Jan-
uary 2009 using keywords "CNP" and "schizophrenia". A
Cochran's  X2-based Q statistical test was conducted to
assess heterogeneity and thus to ensure that each group of
studies was suitable for meta-analysis. When heterogeneity
was detected, the random effects model was adopted; oth-
erwise, the fixed effects model was used. We assessed pub-
lication bias using an ancillary procedure for funnel plot
asymmetry, as described by Egger et al[16]. The significance
of the pooled odds ratios was determined by the Z-test. The
analysis was performed using Comprehensive Meta-Analy-
sis (Version 2.2.046, BIOSTAT).
Results
86 schizophrenics and 94 unaffected controls were geno-
typed and frequencies were calculated (Table 1). There
was evidence of linkage disequilibrium (LD; D'>0.7)
between rs4796750, rs8078650 and rs2070106, which
were considered to reside within the same haplotype
block (Fig 1b). In this block three common haplotypes
accounted for 97% of the variation (Fig 1c).
Real-time PCR was then performed to quantify the expres-
sion level of CNP in the peripheral blood lymphocytes
(PBLs). Some results were discarded on the basis of show-
ing deviation after four replications. We obtained valid
expression data for 79 schizophrenics and 84 controls. As
shown in Fig 2a, the expression of CNP was reduced by
10% in the 79 schizophrenics compared with the 84 con-
trols, but the difference was not significant. To exclude
complicating factors among patients, we compared
expression levels in males and females using unaffected
controls (Fig 2b), with respect to three genotypes of
rs2070106 (Fig 2c). With regard to the schizophrenia sub-
types, we compared the expression levels of the undiffer-
entiated-type, the paranoid-type and other types
(consisting of 3 disorganized-type, 2 catatonic-type and 1
residual-type) as presented in Fig 2d. Fig 2e shows the
effects on the expression of CNP of the four antipsychotics
used, namely, chlorpromazine, risperidone, aripiprazole
and clozapine. However, no statistical difference was
found in any of the above groups.
Table 1: Allele and genotype distribution of SNPs in CNP in schizophrenia patients (case) and control subjects
SNP Sample Allele(Freq.) Genotype(Freq.)
CT C / C C / T T / T
SNP1 Case 148(0.871) 22(0.129) 65(0.765) 18(0.212) 2(0.024)
rs4796750 Control 154(0.846) 28(0.154) 65(0.714) 24(0.264) 2(0.022)
TG T / T T / G G / G
SNP2 Case 147(0.865) 23(0.135) 65(0.765) 17(0.200) 3(0.035)
rs8078650 Control 155(0.842) 29(0.158) 66(0.717) 23(0.250) 3(0.033)
AG A / A A / G G / G
SNP3 Case 66(0.393) 102(0.607) 15(0.179) 36(0.429) 33(0.393)
rs2070106 Control 68(0.370) 116(0.630) 14(0.152) 40(0.435) 38(0.413)
CT C / C C / T T / T
SNP4 Case 101(0.616) 63(0.384) 28(0.341) 45(0.549) 9(0.110)
rs11079028 Control 103(0.579) 75(0.421) 28(0.315) 47(0.528) 14(0.157)
T C T/T T/C C/C
SNP5 Case 25(0.145) 147(0.855) 3(0.035) 19(0.221) 64(0.744)
rs4796751 Control 25(0.133) 163(0.867) 3(0.032) 19(0.202) 72(0.766)BMC Medical Genetics 2009, 10:31 http://www.biomedcentral.com/1471-2350/10/31
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Four independent studies meeting the selection criteria
were included in the meta-analysis investigating associa-
tion between CNP gene and schizophrenia[11,17,18]. The
OR with 95% CIs for the case-control studies are shown in
Table 2. No statistically significant association was found
for rs2070106 and rs8078650 in the allelic analysis. No
publication bias was found.
Discussion
Previous case-control studies in this area have been incon-
sistent in their findings. Peirce et al. reported that the A
allele of rs2070106 was significantly associated with schiz-
ophrenia (P = 0.04) in the white populations of the United
Kingdom and Ireland [11]. However, Japanese[17] and
Chinese[18] studies showed no significant association. In a
recent family-based association study, Voineskos reported
the rs2070106 risk allele G as being associated with schizo-
phrenia in a Caucasian population[19]. Genetic heteroge-
neity may account for the inconsistency among the above
studies, as they are based on different ethnic popula-
tions[20,21]. The LD block structure of CNP varies between
different populations according to the HapMap database
http://www.hapmap.org and other reports. No strong LD
was observed in the population of western European ances-
try (CEU) while a tight LD block was identified in the Jap-
anese and Chinese populations. Additionally, we found
that the allele frequency distribution of SNPs with CNP var-
ied across different populations according to the HapMap
database. For example, the rs2070106 A allele frequency is
32.2% in Asians but 40.8% in Europeans, while the
rs8078650 G allele frequency is 22.2% in Chinese subjects
but 13.3% in the Japanese population. It has been reported
that the power to detect marginal genetic effects may be
influenced by variations in allele frequencies across popu-
lations [22].
We used peripheral blood lymphocytes to investigate gene
expression of CNP. Blood lymphocytes can serve as a con-
Genomic structure, linkage disequilibrium of CNP and haplotype distribution Figure 1
Genomic structure, linkage disequilibrium of CNP and haplotype distribution. a. Genomic structure and locations of 
polymorphic sites in CNP. b. Estimation of linkage disequilibrium (D' value) between five SNPs. c. Haplotype distribution of 
block1.BMC Medical Genetics 2009, 10:31 http://www.biomedcentral.com/1471-2350/10/31
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venient and accessible probe to detect cellular function of
the brain, including gene expression[23]. Critical path-
ways in schizophrenia can be studied in peripheral tissue
as part of the strategy in analyzing functional genomic
convergence[24]. Previous reports on schizophrenia have
suggested that altered expression of genes associated with
myelination of neurons in peripheral blood lymphocytes
is consistent with results from postmortem brain tissue
studies [25]. Our results suggest that expression levels of
CNP  in schizophrenic patients are lower by only 10%
compared to unaffected controls, an insignificant differ-
ence. One previous study identified higher CNP mRNA
expression in females than in males in all thalamic
regions (P  = 0.0014)[13]. However, our own study
detected no difference between females and males either
in the healthy subjects alone or in the combined samples.
Iwamoto et al. reported that the expression of CNP tran-
script was associated with the rs2070106 genotype in the
brains of control subjects[26]. Yet, our study did not rep-
licate this finding with regard to PBLs.
To date, no publication has reported the effect on CNP
expression based on different schizophrenic subtypes and
different drug treatments. Our data showed no statistically
Expression analyses of CNP Figure 2
Expression analyses of CNP. a. Expression level of CNP in the PBLs from unaffected controls and patients with schizophre-
nia. The average level of CNP in controls was defined as 100. No significant difference between controls and cases. b. Expres-
sion level of CNP from unaffected controls between females and males. The average level of CNP in females was defined as 100. 
No significant difference between females and males. c. Expression level of CNP from unaffected controls in the SNP 
rs2070106. The average level of CNP in AG was defined as 100. No significant difference among genotypes. d. Expression level 
of CNP from patients characterized with subtypes. The average level of CNP in controls was defined as 100. No significant dif-
ference among these subtypes. e. Expression level of CNP from patients treated with four separate antipsychotic drugs. The 
average level of CNP in controls was defined as 100. No significant difference among these subgroups.BMC Medical Genetics 2009, 10:31 http://www.biomedcentral.com/1471-2350/10/31
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significant differences with respect to two major diagnosis
subtypes and the four antipsychotic-treating subgroups.
However, we need to be cautious in drawing this conclu-
sion because the sample size is relatively small. The differ-
ent gender distribution between patients and controls also
presents a potential complication. The effect of these fac-
tors on CNP expression requires further study.
Conclusion
To sum up, our expression assay did not support a rela-
tionship between CNP and schizophrenia in the Chinese
population. Similarly, the meta-analysis demonstrated no
significant association between the two polymorphisms
(rs2070106 and rs8078650) and schizophrenia. Ethnic
background is a factor to be considered in further func-
tional research on oligodendrocyte- and myelin-related
pathways and their roles in the pathology and etiology of
psychiatric disorders.
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